GRACE THERAPEUTICS INC

GRCENASDAQ

🏆 #3539 by market capEarnings Nov 16US Equity

$2.12▲ $0.01 (+0.47%)

🌙 After hours$2.12▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 0.5%

7d—

14d—

30d—

1y—

🏦Market Cap

$34M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

65.0%

High

💵FCF Margin

—

⚖️P/S Ratio

171.7x

Expensive

Otter Score

Weak

No chart data available for GRCE.

Trading Snapshot

Day Range: $2.11 – $2.14
52-Week Range: $1.79 – $5.18
Volume: $4.28B
Avg Volume: $3.58B
Shares Outstanding: 16.3M
Next Earnings: Oct 28, 2026

Fundamentals Snapshot

Annual Revenue: $200,948
Last Q Revenue: $48,838
P/E Ratio: —
P/S Ratio: 171.7x
EPS (TTM): $-0.48
Dividend Yield: —

Why Investors Own GRCE

✓High-growth profile — revenue up +50.7% YoY with expanding US Equity exposure.
✓Healthy economics — 32% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$200,948▲ +51.8% YoY

Gross Margin (TTM)

32.0%▲ +3.7% YoY

Operating Income (TTM)

$50,438▲ +51.8% YoY

Free Cash Flow (TTM)

$27,530▲ +51.8% YoY

About GRACE THERAPEUTICS INC

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.

🦦